Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Lyubchenko, Ludmilaa | Emelyanova, Marinaa; b | Shamanin, Vladimirc | Demidov, Leva | Zasedatelev, Alexandera; b | Nasedkina, Tatyanaa; b; *
Affiliations: [a] Clinical Oncology Research Institute, N. N. Blokhin Russian Cancer Research Center of Russian Academy of Medical Sciences, Moscow, Russia | [b] Engelhardt Institute of Molecular Biology of Russian Academy of Sciences, Moscow, Russia | [c] Institute of Molecular Biology and Biophysics, Novosibirsk, Russia
Correspondence: [*] Corresponding author: Tatyana Nasedkina, Laboratory for Biological Microchips, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Russian Federation, Moscow, Vavilova str., 32, Russia. Tel.: +7 9169092440; Fax: +7 4991351405; E-mail:nased@biochip.ru
Abstract: BACKGROUND: The activating mutation BRAF V600E is considered to be a diagnostic cutaneous melanoma (CM) marker important for prognosis and targeted therapy. OBJECTIVE: The aim of this study was to determine the frequency of the V600E mutation in CM patients in Russia and to estimate the influence of the BRAF gene mutation status on prognosis and clinical outcome. METHODS: To ensure mutation detection in FFPE tissue, interlaboratory validation was performed using three different methods: allele-specific hybridisation on a biochip, allele-specific real-time PCR and, in some cases, direct sequencing. RESULTS: Mutation V600E was detected in 49% of patients. The age of disease manifestation was significantly lower in mutated (MT) BRAF patients, and the median age difference between the wild-type (WT) and MT BRAF groups (P= 0.002) was 10 years. A tumour thickness more than 1 mm was also more frequently observed in the MT BRAF group (P= 0.059). Patients from the MT BRAF group were more likely to have ulceration compared to the WT group (P= 0.088). No statistically significant differences were found between the relapse-free, progression-free or overall survival of CM patients in the MT BRAF and WT BRAF groups. CONCLUSIONS: The data obtained show that the V600E BRAF mutation occurred in about half of melanoma patients; it was associated with earlier manifestation of melanoma and likely with more aggressive clinical features.
Keywords: Cutaneous melanoma, BRAF gene, V600E mutation, molecular diagnostics, clinical features
DOI: 10.3233/CBM-150551
Journal: Cancer Biomarkers, vol. 16, no. 1, pp. 153-160, 2016
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl